Thyroid gland presents a wide spectrum of tumors derived from follicular cells. Their behavior varies from the indolent growing, well-differentiated papillary and follicular carcinomas (PTC and FTC, ...

Nat Clin Pract Endocrinol Metab. 2006;2(4):180-181. The fact that PTC is associated with mutually exclusive alterations to MAPK pathway effectors offers intriguing therapeutic opportunities. Ras, RET ...

Please provide your email address to receive an email when new articles are posted on . Researchers evaluated 2,099 patients (1,615 women and 484 men) treated at one of 16 medical centers in eight ...

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene ...

The BRAF gene creates a protein that helps control cell growth. Melanoma is a serious form of skin cancer. If a person has a mutation in their BRAF gene, it can cause a melanoma to grow more ...

Seamless phase II/III trial design with survival and PRO endpoints for treatment selection: Case study of RTOG 1216. Background: BRAF mutations are found in 40% of pts with newly diagnosed PTC but ...

Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial Patients who underwent ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...

—Can you do it? Can you ace these quiz questions about BRAF V600E mutations? They’re all derived from the current literature. At the end of the quiz, compare your score with those of your physician ...

Personalized Medicine. 2013;10(4):405-412. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with ...

Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of ...